Document is current
Any future updates will be listed below
-
Authors
Kolkhir, Pavel https://orcid.org/0000-0001-5380-8132
Grad, Diana Alecsandra
Charalampous, Periklis
Oliveira, Claudia Cruz
Mechili, Enkeleint A.
Unim, Brigid
Pearce, David A.
Maurer, Marcus https://orcid.org/0000-0002-4121-481X
Devleesschauwer, Brecht https://orcid.org/0000-0002-2867-6892
Haagsma, Juanita
- License Information
-
More Information
Article History
First Online: 9 February 2023
Competing interests
: P.K. was a speaker/consultant for Novartis, Roche and ValenzaBio. M.M. is or recently was a speaker and/or advisor for and/or has received research funding from Astria, Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, GSK, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pfizer, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third Harmonic Bio, UCB and Uriach. All other authors declare no competing interests.
